Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004 Jun 24, 2021
MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia with… Jun 23, 2021
MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board Jun 23, 2021
COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme Jun 23, 2021
PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including… Jun 22, 2021
PharmaDrug Advances Product and Clinical Development of Cepharanthine to Treat Infectious Diseases Including COVID-19 Jun 22, 2021
Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelic Jun 17, 2021
